The G-CSF/ATG based HID HSCT using a combination of PB and BM as a graft source has achieved outcomes comparable to those of MSD HSCT for the treatment of acute leukemia, myelodysplastic syndrome, and severe aplastic anemia [12]. Here, CSF3 is linked to acute leukemia.